MBX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$69.00median target· current $60.14 (+14.7%)12 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
49 articles · sorted by datePage 1 of 3 · 49 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-2.170.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$2.99BMid cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 6.84
- P/S (TTM)
- —
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- -25.7%
- Operating margin
- 0.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- —
Last earnings
May 7, 2026 · Estimate $-0.58 · Reported $-0.51
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About MBX Biosciences, Inc. Common Stock
Company profileMBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. The company is headquartered in Carmel, Indiana.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 11711 NORTH MERIDIAN STREET, CARMEL, IN
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$2.99B
Shares outstanding$47.6M
52W high$66.55
52W low$9.63
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent